Advertisement
Canada markets closed
  • S&P/TSX

    22,690.39
    -36.41 (-0.16%)
     
  • S&P 500

    5,505.00
    -39.59 (-0.71%)
     
  • DOW

    40,287.53
    -377.47 (-0.93%)
     
  • CAD/USD

    0.7295
    -0.0003 (-0.05%)
     
  • CRUDE OIL

    80.48
    +0.35 (+0.44%)
     
  • Bitcoin CAD

    93,246.91
    +1,388.32 (+1.51%)
     
  • CMC Crypto 200

    1,399.52
    +68.62 (+5.15%)
     
  • GOLD FUTURES

    2,412.00
    +12.90 (+0.54%)
     
  • RUSSELL 2000

    2,184.35
    -13.94 (-0.63%)
     
  • 10-Yr Bond

    4.2390
    +0.0500 (+1.19%)
     
  • NASDAQ futures

    19,784.00
    +71.00 (+0.36%)
     
  • VOLATILITY

    16.52
    +0.59 (+3.70%)
     
  • FTSE

    8,155.72
    -49.17 (-0.60%)
     
  • NIKKEI 225

    40,063.79
    -62.61 (-0.16%)
     
  • CAD/EUR

    0.6690
    -0.0003 (-0.04%)
     

Why DaVita HealthCare (DVA) is a Top Growth Stock for the Long-Term

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.

While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.

Why This 1 Growth Stock Should Be On Your Watchlist

Different than value or momentum investors, growth-oriented investors are concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, they'll want to focus on the Growth Style Score, which analyzes characteristics like projected and historical earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

ADVERTISEMENT

DaVita HealthCare (DVA)

Denver, CO-headquartered DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

DVA sits at a Zacks Rank #2 (Buy), holds a Growth Style Score of B, and has a VGM Score of A. Earnings and sales are forecasted to increase 13.6% and 5% year-over-year, respectively.

Three analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.39 to $9.62 per share for 2024. DVA boasts an average earnings surprise of 29.4%.

On a historic basis, DaVita HealthCare has generated cash flow growth of 4.9%, and is expected to report cash flow expansion of 12.5% this year.

Investors should take the time to consider DVA for their portfolios due to its solid Zacks Rank rating, notable growth metrics, and impressive Growth and VGM Style Scores.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

DaVita Inc. (DVA) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research